Skip to main content

Table 3 Mean 2-hydroxybenzylamine pharmacokinetic parameters after oral doses

From: Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Parameter2-Hydroxybenzylamine acetate dose
500 mg (n = 6)750 mg (n = 5–6)
Day 1 (first dose)Day 15 (last dose)Day 1 (first dose)Day 15 (last dose)
Ke0.28 ± 0.040.22 ± 0.050.34 ± 0.060.22 ± 0.01
Half-life (h)2.53 ± 0.393.27 ± 0.612.10 ± 0.453.12 ± 0.08
Vd/F162 ± 21183 ± 58225 ± 79264 ± 85
Cl/F44.9 ± 6.338.2 ± 6.773.9 ± 18.558.9 ± 19.9
Tmax (h)1.17 ± 0.680.83 ± 0.611.75 ± 1.252.00 ± 1.22
Cmax (ng/mL)1955 ± 4223177 ± 19931916 ± 5242292 ± 913
Cavg (ng/mL)817 ± 881133 ± 225798 ± 1931190 ± 455
Cmin (ng/mL)285 ± 113324 ± 50261 ± 133484 ± 287
PTF (%)207 ± 67237 ± 110215 ± 87158 ± 58
AUC0–8h (h·ng/mL)6536 ± 7019063 ± 17966385 ± 15479523 ± 3638
AUCinf (h·ng/mL)7620 ± 123010,605 ± 17407186 ± 178011,746 ± 4602
Accumulation Index 1.38 ± 0.15 1.52 ± 0.27
  1. Ke, elimination rate constant; Vd/F, apparent volume of distribution; Cl/F, apparent clearance; Tmax, time to reach maximum plasma concentration; Cmax, maximum observed plasma concentration; Cavg, average observed plasma concentration; Cmin, minimum observed plasma concentration; PTF, peak-to-trough fluctuation; AUC0–8, area under the dosing interval curve; AUCinf, area under the concentration-time curve from zero to infinity.